Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a secondary subject of discussion.
January 2026
In July 2025 the Food and Drug Administration required safety labeling changes to all opioid pain medications to better explain the risks of overdose and addiction. Although the labeling changes improve upon the previous labeling, learn why they fall short of the changes the agency should have required.
March 2025
In September 2024 the FDA announced that all approved immediate-release formulations of the opioid analgesic fentanyl, also known as transmucosal fentanyl, would be removed from the U.S. market by the end of the month. Learn about these risky fentanyl “candy” drugs and why the FDA should never have approved them in the first place.
April 2024
Learn about a recent clinical trial, conducted in Australia, that adds to the evidence from prior research that opioids are no better than placebo and some nonprescription medications (such as ibuprofen) for acute nonspecific musculoskeletal pain.
November 2023
July 2023
Treatment of opioid-use disorder is an important part of the public health response to the opioid epidemic in the United States. Learn about recent research that continues to support the effectiveness and safety of buprenorphine as a treatment for opioid-use disorder.
January 2022
In this month’s news brief, we discuss the FDA’s recent consumer alert warning that children who are accidentally exposed to fentanyl transdermal patches, know by the brand name DURAGESIC, are at risk of life-threatening overdose, even after the patches have been used for the typical full three days.
December 2020
Combining opioids with other central nervous system depressants — mainly alcoholic beverages or benzodiazepines — greatly increases the risk of opioid overdose and death. These dangers are highlighted by new research showing that alcohol and benzodiazepines were commonly co-involved in U.S. opioid overdose deaths in recent years.
October 2017
Hear how drugmaker Alkermes has engaged in a novel but troubling marketing campaign to increase sales of its once-monthly injected version of naltrexone (VIVITROL) for treatment of opioid addiction.
June 2011
This article lists 355 drugs with names that are often confused with similar-sounding drug names. Find out what you can do to prevent getting the wrong drug.
Login
Subscribe